Journal article
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Abstract
BACKGROUND: The interim analysis of the ENZAMET trial of testosterone suppression plus either enzalutamide or standard nonsteroidal antiandrogen therapy showed an early overall survival benefit with enzalutamide. Here, we report the planned primary overall survival analysis, with the aim of defining the benefit of enzalutamide treatment in different prognostic subgroups (synchronous and metachronous high-volume or low-volume disease) and in …
Authors
Sweeney CJ; Martin AJ; Stockler MR; Begbie S; Cheung L; N K; Chowdhury S; Frydenberg M; Horvath LG; Joshua AM
Journal
The Lancet Oncology, Vol. 24, No. 4, pp. 323–334
Publisher
Elsevier
Publication Date
April 2023
DOI
10.1016/s1470-2045(23)00063-3
ISSN
1470-2045